先前接受过卡泊芬净治疗的血液恶性肿瘤患者是导致随后发生念珠菌属真菌血症的危险因素：法国巴黎的一项病例对照研究。
Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.
机构信息
INSERM U 657, Paris, France.
出版信息
Antimicrob Agents Chemother. 2011 Nov;55(11):5358-61. doi: 10.1128/AAC.00690-11. Epub 2011 Aug 22.
Abstract
Infections due to caspofungin-resistant Candida isolates in patients exposed to caspofungin therapy are increasing. We report here a nested case-control study which aimed at identifying factors associated with bloodstream infections caused by Candida spp. having reduced susceptibility to caspofungin (CRSC) in adults suffering from hematological malignancies. In univariate and multivariate analyses, infections with CRSC were associated with caspofungin exposure in the previous 30 days (odds ratio [OR] = 5.25; 95% confidence interval [95% CI], 1.68-16.35) and with an age of ≤ 65 years (OR = 3.27; 95% CI, 1.26-8.50).
摘要
在接受卡泊芬净治疗的患者中，由对卡泊芬净耐药的念珠菌分离株引起的感染正在增加。我们在此报告一项巢式病例对照研究，旨在确定与血液感染相关的因素，这些感染是由患有血液恶性肿瘤的成年人中对卡泊芬净（CRSC）敏感性降低的念珠菌引起的。在单因素和多因素分析中，与 CRSC 感染相关的因素是在过去 30 天内暴露于卡泊芬净（比值比 [OR] = 5.25；95%置信区间 [95%CI]，1.68-16.35）和年龄 ≤ 65 岁（OR = 3.27；95%CI，1.26-8.50）。
相似文献
1
Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.
Antimicrob Agents Chemother. 2011 Nov;55(11):5358-61. doi: 10.1128/AAC.00690-11. Epub 2011 Aug 22.
2
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
Antimicrob Agents Chemother. 2008 Nov;52(11):4181-3. doi: 10.1128/AAC.00802-08. Epub 2008 Sep 15.
3
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.
Antimicrob Agents Chemother. 2011 Feb;55(2):532-8. doi: 10.1128/AAC.01128-10. Epub 2010 Nov 15.
4
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
Antimicrob Agents Chemother. 2006 Jul;50(7):2522-4. doi: 10.1128/AAC.00148-06.
5
Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study.
Int J Antimicrob Agents. 2009 Jul;34(1):95-8. doi: 10.1016/j.ijantimicag.2009.01.006. Epub 2009 Feb 28.
6
Candida and candidaemia. Susceptibility and epidemiology.
Dan Med J. 2013 Nov;60(11):B4698.
7
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
Antimicrob Agents Chemother. 2008 Jun;52(6):2263-5. doi: 10.1128/AAC.01568-07. Epub 2008 Mar 31.
8
Caspofungin for the treatment of candidaemia in patients with haematological malignancies.
Clin Microbiol Infect. 2010 Mar;16(3):298-301. doi: 10.1111/j.1469-0691.2009.02832.x. Epub 2009 Jun 22.
9
Candida krusei--a serious complication in patients with hematological malignancies: successful treatment with caspofungin.
Transpl Infect Dis. 2008 Feb;10(1):66-70. doi: 10.1111/j.1399-3062.2007.00238.x. Epub 2007 May 19.
10
Development of candidemia on caspofungin therapy: a case report.
Infection. 2006 Dec;34(6):345-8. doi: 10.1007/s15010-006-5613-7.
引用本文的文献
1
Mechanisms of multidrug resistance caused by an Ipi1 mutation in the fungal pathogen Candida glabrata.
Nat Commun. 2025 Jan 25;16(1):1023. doi: 10.1038/s41467-025-56269-z.
2
Pichia kudriavzevii (Candida krusei): A systematic review to inform the World Health Organisation priority list of fungal pathogens.
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myad132.
3
Candida auris-a systematic review to inform the world health organization fungal priority pathogens list.
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myae042.
4
Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?
Infection. 2021 Dec;49(6):1107-1131. doi: 10.1007/s15010-021-01640-7. Epub 2021 Jun 16.
5
Treatment of candidemia in a nationwide setting: increased survival with primary echinocandin treatment.
Infect Drug Resist. 2018 Nov 23;11:2449-2459. doi: 10.2147/IDR.S176384. eCollection 2018.
6
Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study.
Infect Dis Ther. 2018 Sep;7(3):309-325. doi: 10.1007/s40121-018-0203-4. Epub 2018 Jun 9.
7
Epidemiology of echinocandin resistance in .
Curr Fungal Infect Rep. 2014 Dec;8(4):243-248. doi: 10.1007/s12281-014-0209-7. Epub 2014 Sep 21.
8
Population Structure of Candida parapsilosis: No Genetic Difference Between French and Uruguayan Isolates Using Microsatellite Length Polymorphism.
Mycopathologia. 2018 Apr;183(2):381-390. doi: 10.1007/s11046-017-0224-7. Epub 2017 Nov 16.
9
Recurrent episodes of Candidemia due to and with acquired echinocandin resistance.
Med Mycol Case Rep. 2016 Dec 7;14:20-23. doi: 10.1016/j.mmcr.2016.12.004. eCollection 2016 Dec.
10
Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1500-8. doi: 10.1128/AAC.01763-15.
本文引用的文献
1
Current perspectives on echinocandin class drugs.
Future Microbiol. 2011 Apr;6(4):441-57. doi: 10.2217/fmb.11.19.
2
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
J Clin Microbiol. 2011 Feb;49(2):624-9. doi: 10.1128/JCM.02120-10. Epub 2010 Dec 8.
3
Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
Diagn Microbiol Infect Dis. 2011 Jan;69(1):45-50. doi: 10.1016/j.diagmicrobio.2010.08.013.
4
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.
Antimicrob Agents Chemother. 2011 Feb;55(2):532-8. doi: 10.1128/AAC.01128-10. Epub 2010 Nov 15.
5
Increase in Candida parapsilosis fungemia in critical care units: a 6-years study.
Mycopathologia. 2010 Oct;170(4):263-8. doi: 10.1007/s11046-010-9322-5. Epub 2010 Jun 4.
6
Breakthrough invasive candidiasis in patients on micafungin.
J Clin Microbiol. 2010 Jul;48(7):2373-80. doi: 10.1128/JCM.02390-09. Epub 2010 Apr 26.
7
Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review.
Int J Antimicrob Agents. 2010 Mar;35(3):211-8. doi: 10.1016/j.ijantimicag.2009.09.020. Epub 2009 Dec 29.
8
Caspofungin-non-susceptible Candida isolates in cancer patients.
J Antimicrob Chemother. 2010 Feb;65(2):293-5. doi: 10.1093/jac/dkp444. Epub 2009 Dec 16.
9
High incidence of Candida parapsilosis candidaemia in non-neutropenic critically ill patients: epidemiology and antifungal susceptibility.
Scand J Infect Dis. 2010;42(2):114-20. doi: 10.3109/00365540903321572.
10
Fungal echinocandin resistance.
Fungal Genet Biol. 2010 Feb;47(2):117-26. doi: 10.1016/j.fgb.2009.09.003. Epub 2009 Sep 19.
Zotero 插件